884 related articles for article (PubMed ID: 28089977)
1. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
[TBL] [Abstract][Full Text] [Related]
2. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
4. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
7. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
Ji Q; Pan W; Zhang D; Hou Y; Wang Z
Front Immunol; 2023; 14():1237209. PubMed ID: 38098481
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
9. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
11. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
12. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
13. Anti-MDA5 Antibody Spectrum in Western World.
Moghadam-Kia S; Oddis CV; Aggarwal R
Curr Rheumatol Rep; 2018 Oct; 20(12):78. PubMed ID: 30382445
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
15. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
[TBL] [Abstract][Full Text] [Related]
16. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
18. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
20. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
Nakashima R; Imura Y; Kobayashi S; Yukawa N; Yoshifuji H; Nojima T; Kawabata D; Ohmura K; Usui T; Fujii T; Okawa K; Mimori T
Rheumatology (Oxford); 2010 Mar; 49(3):433-40. PubMed ID: 20015976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
